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Probing the action of a novel 
anti-leukaemic drug therapy 
at the single cell level using 
modern vibrational spectroscopy 
techniques
Joanna L. Denbigh1,2, David Perez-Guaita  3, Robbin R. Vernooij3, Mark J. Tobin  4, Keith R. 
Bambery  4, Yun Xu1, Andrew D. Southam5, Farhat L. Khanim5, Mark T. Drayson6, Nicholas P. 
Lockyer1, Royston Goodacre  1 & Bayden R. Wood3
Acute myeloid leukaemia (AML) is a life threatening cancer for which there is an urgent clinical 
need for novel therapeutic approaches. A redeployed drug combination of bezafibrate and 
medroxyprogesterone acetate (BaP) has shown anti-leukaemic activity in vitro and in vivo. Elucidation 
of the BaP mechanism of action is required in order to understand how to maximise the clinical benefit. 
Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Synchrotron radiation 
FTIR (S-FTIR) and Raman microspectroscopy are powerful complementary techniques which were 
employed to probe the biochemical composition of two AML cell lines in the presence and absence 
of BaP. Analysis was performed on single living cells along with dehydrated and fixed cells to provide 
a large and detailed data set. A consideration of the main spectral differences in conjunction with 
multivariate statistical analysis reveals a significant change to the cellular lipid composition with drug 
treatment; furthermore, this response is not caused by cell apoptosis. No change to the DNA of either 
cell line was observed suggesting this combination therapy primarily targets lipid biosynthesis or effects 
bioactive lipids that activate specific signalling pathways.
Acute myeloid leukaemia (AML) is an aggressive cancer that leads to a build-up of non-differentiated, dys-
functional cells from the myeloid lineage. Without treatment, patients can die from impaired haemopoiesis 
within weeks of diagnosis and unfortunately responses to current treatments and overall survival of patients 
post-treatment generally remains poor1.
Current AML treatment is centred on short cycles of intensive cytotoxic chemotherapy to kill the cancer 
cells, however, this treatment can disrupt the production of healthy blood cells. Continuous use of intensive 
chemotherapy is precluded because of the high levels of toxicity that affect haemopoiesis and cell division, which 
is important in maintaining the integrity of the body’s mucosal surfaces. This dose-limiting toxicity prevents 
escalation of chemotherapy to treat resistant disease and precludes its use in many older frailer individuals who 
account for a high proportion of AML patients2. Accordingly, there is an urgent need for low toxicity anti-AML 
therapies that can be used both as an adjunct to chemotherapy and in between chemotherapy cycles. Continuous 
low toxicity therapy is a novel strategy to manage AML by providing good quality survival even without total 
eradication of the disease.
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Drug redeployment (repurposing) represents an attractive therapeutic option that involves the use of existing 
drugs for treatments which they were not originally intended and has the potential to offer less toxic therapies 
than chemotherapy3. The redeployed combination of the cholesterol lowering drug, bezafibrate, and the female 
contraceptive, medroxyprogesterone acetate (combination denoted BaP) has anti-leukaemic and anti-lymphoma 
activity without haematological toxicity both in vitro and in patients4–7. Mass spectrometry lipidomics of BaP 
treated AML cell lines has recently demonstrated that BaP slows de novo fatty acid biosynthesis, particularly 
the synthesis of monounsaturated fatty acids, which plays a key role in BaP-related AML cell killing8. This has 
relevance in the wider cancer field where tumour cells often have up-regulated fatty acid synthesis and inhibi-
tion of this process leads to tumour cell death9, 10. The effect of BaP on de novo lipogenesis also led to a broad 
change in the overall phospholipid acyl chain composition, which may play a role in cell killing8. A spectroscopic 
investigation of the action of BaP at the single cell level offers an original insight into the mode of action of this 
combination therapy in which living cells can be monitored with BaP treatment. This eliminates the need for 
the extraction of lipids or metabolites from cells; thereby giving a more holistic picture of the cell biochemis-
try. Employing high-resolution techniques such as Fourier Transform infrared (FTIR) spectroscopy and Raman 
microspectroscopy provides new insights into the drug mechanism of action at sub cellular resolution.
FTIR and Raman microspectroscopy have both developed significantly in the last decade as powerful tools 
for probing the molecular structure of biological specimens such as tissue, cells and serum11–19. They are com-
plementary techniques with different selection rules - FTIR spectra arise from the absorption of radiation from 
functional groups with a permanent dipole moment; whereas Raman spectra result from the inelastic scattering 
of light from molecules where the dipole moment is induced by the incident laser which causes a change in the 
intrinsic polarizability of the molecule. Molecules or functional groups that strongly scatter Raman light tend be 
more symmetric and chromophoric, whereas strong IR absorbers are usually more asymmetric in terms of their 
electronegativity when vibrating. The techniques are capable of providing a rapid, rich biochemical ‘fingerprint’, 
which on interpretation are extremely informative in both a research and more recently, a diagnostic setting20–24. 
Probing drug-cell interactions with spectroscopic techniques has become increasingly popular and can contribute 
to the understanding of the mode of action of the drug at a cellular level25, 26. The majority of spectroscopic cel-
lular studies reported to date are on cells that have been chemically fixed and are therefore often in a dehydrated 
state17, 18, 23, 27–29. Fixation aims to preserve the structural and biochemical constituents of cells in as close to in vivo 
conditions as possible and is widely accepted in the field of spectroscopy29. It also has the advantage of preventing 
cells from moving outside of the field of view or away from the irradiation source during cell imaging. However, 
cell dehydration during fixation changes the conformation of the DNA from the B-form to the more disordered 
A-form30 which renders the A-form DNA bands weaker and broad when compared to B-form bands making 
them difficult to discern from other macromolecules like protein, RNA and carbohydrates30, 31. This is pertinent 
when trying to assess whether or not there has been intercalation of a drug treatment with the DNA resulting 
in either conformational change or denaturing of the molecule and exemplifies that there are advantages gained 
through the study of live cells over that of fixed cells. Further disadvantages associated with fixation are the use 
of chemicals which can interfere with the inherent biochemical signature of the cell, thus potentially altering 
the spectrum32 and that light scattering effects (due to the difference in refraction indices between the cell and 
surroundings) are commonly observed in FTIR, which must be subsequently corrected for during spectral inter-
pretation. Thus, there are significant benefits to be had for probing a cell in its hydrated state for a more accurate 
view of the nature of intracellular biochemical species in a tested physiological condition. Employing the high 
fluency and superior brightness of a synchrotron beam33 enables such in vivo analysis to be performed in real time 
with cells remaining in their growth medium, thereby eliminating the requirement for any potentially detrimen-
tal sample preparation. The ability to probe single cells, one by one is extremely desirable, ensuring information 
obtained is specific to the living cell in question, rather than that averaged over a heterogeneous cell population, 
which can also include cell debris and cells that are undergoing cell death.
To date, biochemical and morphological classification of healthy versus diseased cell lines has been well 
demonstrated with FTIR and Raman spectroscopies34, 35 and in the field of leukaemia, spectroscopic studies have 
investigated leukaemia cell classification27, 36, 37 drug cytotoxicity38 and leukemic cell apoptosis39, 40. Only a few 
studies have employed spectroscopic techniques to specifically probe the nature of AML41–43 and as far as we are 
aware, there are no reports which combine FTIR and Raman spectroscopy to study targeted anti-AML drug-cell 
interactions. Furthermore, typical cells reportedly studied in many drug-cell interaction situations are adherent 
cells, which are amenable to growth onto a substrate for analysis and are therefore somewhat easier to manipulate 
than suspension cells for the purpose of single cell microspectroscopic analysis. Here we present for the first time, 
a spectroscopic interpretation of the action of the recently reported BaP drug therapy in two AML suspension 
cell lines, HL60 and K562. Cells reported here were analysed live (synchrotron-FTIR), dehydrated (ATR-FTIR) 
and fixed (Raman); a diversity which contributes to a broad spectroscopic picture of drug action. The large num-
ber (>800) of single cells reported here gives further confidence to the power of the techniques, as described by 
statistical models for data interpretation. These data give an in situ interpretation of the effect of BaP treatment 
on AML cells.
Results and Discussion
Direct infusion mass spectrometry analysis of drug-treated AML cells shows that bezafibrate and medroxypro-
gesterone acetate are taken up by the cells as illustrated in Supplementary Figure S1. The combination of these 
drugs (denoted BaP) has a potent anticancer effect on the HL60 and K562 cell lines that are used in this study7, 8.
Overview of FTIR Spectra. Data are presented for both ATR and S-FTIR analyses. Cells analysed by 
ATR-FTIR were sampled from a heterogeneous cell pellet which predominately consisted of viable cells, but 
was also likely to contain cells in varying stages of necrosis and cell debris from cells which may have undergone 
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apoptosis in culture. A significant advantage of this technique is that it is easily accessible, portable and inex-
pensive. It also minimises scattering and other baseline contributions, as shown in the raw spectra presented in 
Supplementary Figure S2. However, cells were dehydrated, thus limiting the biochemical information that can be 
derived from resulting spectra. Exploiting the superior properties of the synchrotron beam33 allows transmission 
of light through aqueous environments and the two windows of the sample holder, thus enabling the analysis 
of live single hydrated cells. Cells were clearly visible under the microscope to confirm their viability and a ran-
domised selection of single cells was selected from each aliquot of cells in this study. Averaged second derivative 
spectra for K562 and HL60 cells analysed with both techniques are shown in Fig. 1 (second derivative spectra 
shown to enhance spectral features). The C-H stretching region (3050–2800 cm−1) as well as the lower wavenum-
ber cell fingerprint region (shown as 1800–900 cm−1 for ATR-FTIR and 1800–1200 for S-FTIR) are overlaid for 
control and 24 hour BaP treated cell spectra for both ATR-FTIR (Fig. 1a) and synchrotron-FTIR (Fig. 1b) analysis 
of each cell line, respectively.
Spectra measured by ATR were acquired for air-dried cell pellets, whereas the spectra obtained by S-FTIR 
were only of live hydrated cells. The difference in hydration states significantly affects both band intensity and 
width. In the hydrated state the DNA is in the B-DNA form and the bands appear sharper and more intense com-
pared to when the cells are dehydrated and the A-DNA form dominates, which is more disordered compared to 
B-form31. The difference in hydrogen bonding between hydrated and dehydrated cells also affects the width and 
position of the amide modes from proteins.
Orthogonal partial least squares-discriminant analysis of FTIR data. Orthogonal partial least 
squares-discriminant analysis (oPLS-DA)44 was performed using the 3059–2715 cm−1 and the 1819–1223 cm−1 
regions for the synchrotron data and using the 3133–2806 cm−1 and the 1840–862 cm−1 regions for the ATR data 
for control and 24 hour drug treated cell spectra. Figure 2 shows the scores of the first oPLS-DA latent variable 
(LV) for each cell type, K562 (Fig. 2a) and HL60 (Fig. 2b) with LV1 clearly distinguishing drug treatment (red) 
from control cells (green). The same trend was observed for ATR spectra and is shown Supplementary Figure S3. 
Although the LV1 calibration values are not good indicators of the classification performance due to overfitting 
Figure 1. Normalised, mean second derivative spectra from 9 replicates for ATR analysis (a) of HL60 and K562 
control and BaP treated cells and 3 replicates for each of 2 trials for S-FTIR analysis (b), incorporating a total of 
441 individual cells (HL60) and 385 individual cells (K562). The high wavenumber (3050–2800 cm−1) region 
is predominated by the νas(CH3), νas(CH2), νs(CH3) and νs(CH2) stretches at 2955, 2920, 2870 and 2850 cm−1 
respectively, which arise from cellular lipid species. Synchrotron data were not collected below ca 1200 cm−1 and 
the plot is generated so that the x-axis is on the same wavenumber scale.
www.nature.com/scientificreports/
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issues, they are necessary to interpret the direction of the oPLS-DA first loading vector. A more reliable estimation 
of the model quality was obtained by the cross validation results (Venetian blinds, 10 splits), which indicated a 
good classification performance in the four cases, given error rates of 15% (4LVs), 0% (3LVs), 15% (2LVs) and 
11% (1LV).
Further validation of the oPLS-DA model was obtained by using partial least squares discriminant analysis 
(PLS-DA). The classification model for the PLS-DA computed across the spectral region 3100–1100 cm−1 for all 
S-FTIR cells analysed, with no outliers removed, can be seen in Fig. 3. Bootstrapping was performed 1000 times 
to permute whether the cell was drug treated or not. The output shows two discrete distributions; a ‘real’ (in blue) 
and ‘null/random’ (in red) model, these models have good correct classification rates (CCR) of an average of 
94.36% for K562 and 78.14% for HL60 cells.
When comparing data acquired between the two cell lines, it is apparent that HL60 cells (which are on average 
typically smaller than K562 cells) show a greater distribution in spectra than K562 cells. This is understandable, 
given that the aperture size employed and average size of HL60 cells is comparable, thereby a portion of HL60 
cells at less than 10 µm in diameter would contribute non –cellular features to the spectra and are were more likely 
to appear as outliers.
FTIR spectral interpretation. A visual inspection of the ATR spectra (Fig. 1a) reveals an apparent change 
in the intensity of signals in the high wavenumber (3050–2800 cm−1) region, predominated by the νas(CH3), 
νas(CH2), νs(CH3) and νs(CH2) stretches arising from lipid species within the cell, and located at 2955, 2920, 2870 
and 2850 cm−1. Specifically, it appears that there is an overall increase in signal intensity for both the asymmetric 
and symmetric methylene ν(CH2) stretches with BaP treatment and a corresponding decrease in intensity for 
the methyl ν(CH3) asymmetric and symmetric stretches (in the second derivative spectra a peak minimum cor-
responds to the maxima intensity in the underivatised spectra). This trend is also observed in the synchrotron 
data as shown in Fig. 1b, which exhibits an overall increase in methylene intensity (shown as peak minima). 
The fingerprint region of the spectra in Fig. 1 is dominated, as expected, by the amide bands I (1639 cm−1) and 
II (1535 cm−1) arising from ν(C = O) stretching mode (Amide I) and δ(N-H) bending and ν(C-N) stretching 
modes of peptide linkages (Amide II), which typically represent total cellular protein. The fingerprint region also 
contains more subtle features, often appearing as small inflections of a peak more prominent in second derivative 
spectra, for example a change in DNA conformation can be determined by considering the position of the asym-
metric phosphate stretching vibration observed at 1220 cm−1 in B-DNA and 1235–40 cm−1 in A-DNA, which is 
discussed later.
Figure 2. Scores plots for the first oPLS-DA component for S-FTIR spectra of control (green) and BaP treated 
(red) K562 (a) and HL60 (b) cells. Each point represents a K562 single cell (a) and HL60 single cell (b).
www.nature.com/scientificreports/
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An inspection of the first loadings vector from the oPLS-DA confirms that the main contribution to the 
separation observed in the scores plot is from the aforementioned methylene moieties, with prominent fea-
tures observed in the high wavenumber region at 2920 cm−1 and 2850 cm−1. The first loadings vector from the 
oPLS-DA, with asymmetric and symmetric ν(C-H) stretches annotated can be seen in Fig. 4. Here, the loadings 
from both synchrotron and ATR spectra are overlaid showing consistent loadings and good correlation between 
data sets obtained with these two techniques. Loadings shown for the synchrotron spectra are noisier than spectra 
obtained with ATR likely due to differing amounts of biomaterial analysed; synchrotron data are averaged over a 
cell population of a few hundred cells for each cell line, however thousands of cells would have been present in the 
aliquot sampled and dried on the ATR element. Despite cells being hydrated for S-FTIR analysis and dehydrated 
in the case of ATR, both techniques produce concordant results and the predominant spectral changes arise 
from disruptions to cellular lipid composition. There is less of an observable contribution to the discrimination 
between control and drug treated cells in the lower wavenumber spectral region.
Figure 3. Classification model for PLS-DA of S-FTIR analysis of whole cell populations for K562 (a) and HL60 
(b) cells showing classification rates for real (blue) and random (red), with a CCR of 1 being a 100% correct 
classification. The embedded tables are the average confusion matrices with rows representing predicted 
classification and columns representing experimental.
Figure 4. oPLS-DA loadings vectors overlaid for S-FTIR (red) and ATR-FTIR (blue) loadings in the high 
wavenumber lipid region, for K562 (a) and HL60 (b) cells.
www.nature.com/scientificreports/
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The apparent change in methylene to methyl ratios in data acquired for BaP treated cells was further explored 
by extracting spectral peak areas for all single cells analysed with S-FTIR. Figure 5 shows peak area ratios for 
asymmetric and symmetric stretches of methylene and methyl moieties for K562 (Fig. 5a) and HL60 (Fig. 5b) 
cell populations. The box plots include all synchrotron spectra acquired, each point representing a cell; the spread 
therefore representing inter-cell variability across biological replicates spanning two trials. Data clearly show an 
increase in the methylene to methyl ratio with drug treatment for both asymmetric and symmetric stretches. A 
concurrent trend is also observed for ATR spectra acquired from cell pellets from 9 biological replicates, with data 
shown in Supplementary Figure S4.
PLS-DA confirms the grouping according to methylene to methyl peak area ratios for BaP treated and control 
cells and p values for each are detailed in Supplementary Table S1. The CH2:CH3 ratios proving to be significant 
in both cell lines (p = <0.05) for both synchrotron and ATR analyses.
A biological interpretation of these data is interesting since an increase in CH2:CH3 ratio indicates that lipids 
in drug treated AML cells show an overall change in saturation state with BaP treatment when compared with 
control cells. Lipid composition in drug treated cells may consist of a greater number of acyl chain double bonds 
at a chain end position or data could suggest increased lipid saturation in mid acyl chain positions. To gain fur-
ther insight into this picture, Raman microspectroscopy was employed to image control and drug treated single 
cells and data for this is presented later.
Drawing conclusions on drug mode of action based on a consideration of just the lipid region of the spectra 
can, however, be somewhat short-sighted. Similar changes in lipid biochemistry can also be observed in cells 
undergoing various stages of cell death from necrosis through to apoptosis. The increase of lipids in this case is 
reportedly due to a number of cell membrane processes such as blebbing and vesicle formation, which can give 
rise to an increase in CH2 absorption observed in the spectra45. This implies that many drug-cell interaction 
studies, which report lipid changes, might in fact just be monitoring the death of a cell due to drug treatment and 
this has recently caused some concern in the spectroscopy community. In this study, the previously described 
BaP treatment is known to differentiate HL60 cells further and induce apoptosis in K562 cells, but not within the 
24 hour treatment period used in this study7. When a cell enters apoptosis, the DNA shifts to a more disordered 
state, and the DNA signal in an infrared spectrum typically decreases46. A shift in the DNA band can also be 
observed in cells which have been treated with a drug known to intercalate with DNA, whose mode of action is 
such that base pairing is interrupted and unravelling from orderly B-DNA to the more disordered A-DNA form 
occurs47.
 Care must be taken when interpreting the data to ascertain if the spectra show evidence of drug induced 
biochemical changes or are indicative of cell death. Here, the major DNA peaks have been explored to assess if 
one of the targets of BaP could in fact be DNA and to confirm that what was being monitored in this study was 
not simply cell death. One of the vibrations as a marker for the latter hypothesis is the carbonyl vibration for 
Figure 5. Box and whisker plots for significant changes (p < 0.05, see Supplementary Table S1) in peak area 
ratios of methylene to methyl stretching vibrations between control and 24 h BaP treated cells analysed by 
S-FTIR. a. shows peak area ratios 2920:2955 cm−1 for asymmetric C-H stretching and 2850:2870 cm−1 for 
symmetric C-H stretching for K562 cells and b. shows the same ratios for HL60 cells. The median of each box 
plot can be compared to describe the changes in lipid peak area ratios with drug treatment; with the maximum 
values, minimum values and outliers showing the spread in inter-cell variability within population sizes of 
385 cells for K562 and 441 cells for HL60. Extreme outliers (n < 10) were removed from the plot for visual 
appearance, however all cells analysed were included in the data analysis.
www.nature.com/scientificreports/
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protein linking in the amide I band at 1657 cm−1 which has been reported to significantly decrease with apopto-
sis48. A visual inspection of the spectra in Fig. 1 indicates no obvious change in amide I signal intensity with BaP 
treatment. Perhaps more diagnostic though is the position of the asymmetric phosphate stretch of DNA which is 
reported to shift from 1220 cm−1 to 1240 cm−1 with a conformation change from B-DNA to A-DNA30, a phenom-
enon which can occur during drug treatment and also during cell dehydration. Fully hydrated DNA exists in the 
B-conformation and one of the main markers for a B- to A-DNA transition is the shift of νasym(PO2−) to a higher 
wavenumber. As such, this change can only be confidently observed in synchrotron spectra for which cells are 
hydrated during data acquisition. Figure 6 shows peak area ratios between control and drug treated cells for the 
asymmetric phosphate stretch of DNA, to look for a shift in peak maxima indicating a change in DNA conforma-
tion. For this scenario we have a null hypothesis, with DNA signals not responding in a manner indicative of cell 
death. The absence of a significant change in this peak area ratio is further confirmed in Supplementary Table S1, 
with the 1240:1220 peak ratios showing very high p values, thereby not being significant. This information, cou-
pled with the apparent absence of change for the amide I peak intensity strongly suggests that DNA is not a target 
of BaP therapy. This is of key significance from an in vivo biological perspective, because it could explain why the 
drug combination BaP showed little or no haematological toxicity to healthy cells in a small cohort of patients 
recruited for clinical trial4. If BaP was interfering with the DNA of a cell, one would expect that to be a fairly non 
selective process and thus signs of DNA disorder across all cells might be expected.
Raman Mapping of single cells to further characterise BaP-induced lipid changes. Raman map-
ping was employed to further probe drug-induced biochemical changes observed with FTIR and to provide 
sub-cellular spatial information regarding these changes. The resulting data matrix for each cell map obtained was 
refined by removing background pixels by evaluating the signal-to-noise ratio of the Raman spectra. A cut-off 
threshold of 2 efficiently removed all the background pixels as shown in Fig. 7. Single cell images of cell features 
were derived using fuzzy c-means clustering (FCM) analysis on all spectra obtained from K562 formalin fixed 
control and drug treated cells (n = 6 and n = 5 respectively). In this process, each pixel is associated with a fuzzy 
membership value so that the gradient from one cell compartment to another can be well presented. Figure 7 
shows a representative K562 control cell (Fig. 7a) and drug treated cell (Fig. 7b) with the left most images showing 
the single cell image refined through the removal of background pixels by evaluating the signal-to-noise ratio of 
the Raman spectra. The cell membrane is clearly defined (yellow) around the outer perimeter of the cell in Cluster 
1 and internal cell structures clearly observable (yellow) in Cluster 2.
The confusion matrices for the PLS-DA computed across the entire spectral region for all 11 K562 formalin 
fixed cells are detailed in Supplementary Table S2, with correct classification rates of 95.23% for BaP treated cells 
and 89.11% for control cells of combined clusters (all cell spectra). Despite there being no obvious changes by eye 
when comparing the images with each other, the VIP PLS-DA scores plots shown in Fig. 8 clearly highlight three 
distinct Raman peaks as key to this classification which all arise from cellular lipid changes with BaP treatment. 
Mapping the spatial distribution of spectral features across single cells has identified that the aforementioned lipid 
changes appear to be consistent across the whole cell, with no obvious regional differentiation between membrane 
lipids and intra-cellular lipids.
Figure 6. Box and whisker plots of peak height ratios for the asymmetric phosphate stretch at 1240:1220 cm−1 
calculated for the entire cell population of K562 cells (a) and HL60 cells (b) analysed by S-FTIR. The median 
line indicates no significant shift in asymmetric phosphate stretch peak position between control and drug 
treated cells for either cell class.
www.nature.com/scientificreports/
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Biological interpretation of observed cellular lipid changes. All three spectroscopic techniques 
employed in this study revealed an increase in the CH2:CH3 ratio of lipid peaks in the high wavenumber spectral 
region of drug treated cells which indicates a change in cellular lipid saturation state with BaP treatment and 
demonstrates good consistency between the analytical techniques. From the FTIR data alone it is not possible to 
infer specifically what lipid saturation change this refers to. However, in the case of the Raman spectra the peak 
observed at 1440 cm−1 decreases (reportedly proportional to total lipid saturation) indicating an increase in lipid 
unsaturation with BaP treatment. This band would also have contributions from methyl and methylene modes 
from amino acid side chains of proteins but the fact that there is also a correlation with the increase in intensity 
of the bands in the methyl/methylene stretching region (3000–2800 cm−1) indicates that the major changes are 
the result of changes in lipids and not proteins. This is consistent with our previous mass spectrometry lipidomics 
study where BaP treated AML cells had more unsaturated phosphatidylcholine than control cells8. An explanation 
Figure 7. FCM images of a representative control and BaP treated K562 formalin fixed cell.
Figure 8. Variable Importance in Projection (VIP) scores for PLS-DA of K562 control and drug treated cells 
showing three Raman lipid peaks.
www.nature.com/scientificreports/
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for this altered lipid saturation is that BaP has been shown to decrease de novo fatty acid synthesis—synthesis of 
saturated and monounsaturated fatty acids and increase uptake of polyunsaturated fatty acids from the media8.
One novel aspect of these data is the visualisation of increased lipid unsaturation at the single cell level and 
data suggest that the BaP-induced change in saturation state is uniform across the cell. Increasing lipid unsatura-
tion typically renders these biomolecules more fluid which has implications for cancer cell biology and survival. 
The phenomenon of high rates of de novo lipogenesis observed in cancer cells enables them to synthesise new 
cell membranes during rapid proliferation and it also allows cancer cells to be more independent in terms of 
their energy supply and biochemical need for growth. Enhanced lipogenic phenotype is characterised by lipids 
with saturated or mono-unsaturated acyl chains in a number of different cancer cell lines which is significant in 
terms of protecting them from lipid peroxidation and apoptosis49. During lipid peroxidation, free radicals remove 
electrons from cell membrane lipids, producing oxidised lipid species and small molecule reactive oxygen species 
(ROS), which could jeopardise the stability and longevity of a tumour cell49. This is pertinent because BaP induces 
high levels of ROS, which is associated with its anticancer effect7. Therefore the actions of BaP may involve both 
an increase in production of ROS and an increase in cell susceptibility to ROS. Membrane rigidity (arising from 
increased lipid saturation) is also implicated in cell resistance to anti-cancer drugs by impairing uptake of drugs 
through the membrane50 and any increasing lipid unsaturation observed within cells could be a mechanism to 
preventing drug resistance.
Considering the important role that saturated lipids play in cancer cell function and survival, spectroscopic 
data reported here suggests that the BaP-induced increase in lipid unsaturation observed is likely to play a role in 
its anti-cancer activity.
Conclusion
Employing a multi-platform spectroscopic approach to probe the action of BaP on HL60 and K562 cell lines 
affords a comprehensive picture of the effect of drug therapy on the biochemical nature of the cells and allows us 
to further understand the targets of BaP. Data reported for S-FTIR, ATR-FTIR and Raman microspectroscopy 
strongly indicate that lipid biochemistry is a significant target of BaP; furthermore, the ability of S-FTIR to probe 
cells in a hydrated state enabled ‘drug-DNA’ interaction to be probed and indicated that DNA is unlikely to be a 
target of this therapy.
A significant increase in methylene functionality with drug treatment indicates that AML cells with increased 
unsaturation post-BaP treatment are representative of the more typical biochemistry of non-cancerous cells. 
Raman microspectroscopy supported the findings of FTIR and added a further dimension to the study by pro-
viding spatial information of lipid distribution which suggested that BaP-induced saturation change is uniform 
across a single cell.
Materials and Methods
Cell Culture. Acute myeloid leukaemia (HL60 and K562) cell lines were cultured in RPMI 1640 medium 
(+L-Glutamine) supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) penicillin-streptomycin (Life 
Technologies, ThermoFisher) and maintained in exponential growth (between 0.25–1.5 × 106 cells/mL) at 37 °C 
with 5% CO2. Cells were cultured in situ at the Australian Synchrotron (Clayton, Victoria) for one week prior to 
experimentation.
Drug Treatment. Cells were seeded at 0.5 × 106 cells/mL in T-25 flasks (vented) and treated with 0.5 mM 
bezafibrate in DMSO and 5 µM medroxyprogesterone acetate in ethanol (combination treatment denoted ‘BaP’)7. 
Control flasks (from the same seeding flask as drug treated cells) received equal volumes of ethanol and DMSO. 
Cells were incubated for 24 hours at 37 °C with 5% CO2.
Preparation of Cells. Control and BaP treated cell suspensions of HL60 and K562 in growth media were 
removed from the incubator at 24 hours and centrifuged at 500 × g for 5 min. The supernatant was discarded, 
leaving a small volume of liquid in the cell pellet.
For Synchrotron-FTIR analysis, minimal sample preparation was required; the solution was agitated gently 
to release the cell pellet with a pipette tip and 2 µL of the concentrated cell suspension was removed and gently 
placed on a CaF2 disc seated in a purpose-built microfluidics sample accessory device as previously described51. 
This ensured cells were in a fully hydrated state for analysis while the microfabricated gasket thickness was 
selected to ensure the cells were gently held between the upper and lower windows of the chamber and remained 
stationary during measurement.
For ATR-FTIR analysis, the cell pellet was washed twice with physiological saline solution with centrifugation 
performed between washes. The remaining cell pellet was treated as stated above with 2 µL of the concentrated 
cell suspension being placed directly onto the diamond ATR window and allowed to air dry thoroughly before 
recording spectra.
For Raman analysis, the cell pellet was re-suspended in Dulbecco’s phosphate buffered saline (PBS) solution, 
500 µL (Sigma-Aldrich). The solution was well agitated, transferred into a microcentrifuge tube and centrifuged at 
500 × g for 5 min using a small bench-top centrifuge. The supernatant was removed and the cell pellet was washed 
3 times with PBS, 500 µL. The cell pellet was resuspended in approximately 50 µL (containing approximately 3 
million cells) and spotted onto a CaF2 disc and the excess suspension drawn off the disc to leave a sparse mon-
olayer of cells remaining. Once the surface of the disc had dried, excess formalin (10% formalin solution, buffered 
pH 7.0, VWR) was spotted onto the surface to fix the cells. The formalin was left on the disc surface for 15 min 
then removed by gently shaking off the excess and the fixed cells were subsequently washed with 3 × PBS, 500 µL 
and air dried prior to analysis.
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Synchrotron-FTIR Measurements. Synchrotron-FTIR measurements were recorded using the FTIR 
microspectroscopy beamline at the Australian Synchrotron. For the microspectroscopy beamline the beam 
is directed to a Bruker Hyperion 3000 IR microscope (Bruker Optics GmbH., Ettlingen, Germany) equipped 
with a liquid-nitrogen-cooled mercury-cadmium-telluride (MCT) detector with a × 36 IR objective (NA = 0.5). 
The Hyperion 3000 microscope is coupled to a Bruker Vertex 80 v spectrometer and data collection was carried 
out using Bruker’s OPUS version 6.5 software, with an additional 3D analysis package (Bruker Optics GmbH., 
Ettlingen, Germany). The Hyperion microscope and the sample were purged with dry nitrogen gas to minimize 
water vapour contributions and carbon dioxide in the spectra. Spectra were recorded in transmission mode in 
the region 4000–900 cm−1 with a spectral resolution of 6 cm−1 using an aperture size of 10 × 10 µm. This aperture 
size was chosen to reflect the typical cell sizes of approx. 10–14 µm (HL60) and 12–16 µm (K562). Background 
spectra of a cell free region containing only cell culture media were taken every 5 spectra to account for any 
non-cell specific contributions to the signal and beam current fluctuations and 64 interferograms were co-added 
per measurement in order to obtain a good signal-to-noise ratio. Spectra were collected from at least 385 single 
cells for each cell line, which accounts for biological replicates and analysis on different days. The exact number of 
cells studied for each cell line is specified in the legend of Fig. 1.
ATR-FTIR Measurements. ATR-FTIR analyses were performed on an Agilent 4500a portable FTIR spec-
trometer equipped with a triple reflection diamond ATR sample interface. Spectra were collected at 4 cm−1 res-
olution with 64 co-added interferograms corrected against a clean diamond background. For each cell line, 9 
biological replicates were analysed for both drug treated and control cells.
Raman Measurements. Raman spectroscopic analysis was performed using a Renishaw inVia Raman 
microscope (Renishaw plc., Wooton-under-edge, UK). Raman spectra and maps were obtained; using a 532 nm 
excitation beam, ~30 mW at the sample, ×50 objective and exposure times of 10 s for point spectra and 6 accu-
mulations of 1 s (6 s in total) for mapping. StreamLineHR mapping (which uses a laser-spot focus) was carried 
out in high confocal mode, at a step size of 0.5 μm. Data were processed using algorithms in the Renishaw WiRE 
software and using scripts written in MATLAB (The Mathworks Inc. Natik, U.S.A) during which the spectral 
hypercube of each map was analysed to produce images.
FTIR Data Analysis. Pre-processing of the spectra was carried out in MATLAB. For both cell lines, all spec-
tra acquired were used in the data modelling. Raw spectra were corrected for baseline fluctuations and any scaling 
effects due to different pathlengths, using extended multiplicative signal correction (EMSC)52. To avoid intro-
ducing any further artefacts into the data set, no further pre-processing algorithms were employed. Following 
EMSC correction, the spectra were cropped to the specific regions of interest to be analysed (3100–2800 cm−1 for 
the lipid region and 1800–1100 cm−1 for the fingerprint region). ATR-FTIR spectra were processed as the second 
derivate to enhance spectral features. All spectral assignments have been made according to widely cited literature 
references19, 53, 54.
Statistical Analysis. Orthogonal Partial least squares-discriminant analysis (oPLS-DA). Prior to the 
oPLS-DA, spectra data matrix was pre-processed using a) Savitzky-Golay filtering based second derivative (order: 
2, window: 9 points), b) standard normal variate spectra normalization, c) Pareto scaling variable pre-processing 
and d) mean centring. Data processing was performed employing MATLAB using the routines available on the 
PLSToolbox package from Eigenvector Research Inc. (Manson, USA).
Bootstrapping Validation. In order to validate the models generated by partial least squares-discriminant anal-
ysis (PLS-DA) bootstrapping with replacement was used for the synchrotron FTIR spectra. In this resampling 
process a 1000 bootstraps were undertaken and in each bootstrap each training set contained on average 63.2% 
of all samples, and each test sets included the remaining 36.8% samples. Statistics were then generated for the 
1000 models in terms of correct classification rates and confusion matrices. This technique gives well represented 
estimates of the average model and is therefore less likely to be biased55.
Raman Data Analysis. Raman maps for 5 control cells and 6 drug treated cells were pre-processed in 
WiRE software (Renishaw plc.) for cosmic ray removal and further manipulated according to in-house scripts in 
MATLAB. Signal-to-noise (SNR) assessment was performed using Morphological Scores (MoS)56. Fuzzy c-means 
clustering algorithm was employed to image features of the cell and subsequently PLS-DA was able to differentiate 
between the two cell classes. The PLS-DA models were validated by using a k-fold cross double cross-validation 
(CV)57 where k is the number of cells, i.e. the spectra of an individual cell were held out as the test set and the 
model was built on the remaining spectra. The model was then applied to the test set spectra to predict their class 
membership. This procedure was repeated k times until each cell had been held out as test set for once. Within 
each CV procedure, the number of PLS-components was chosen by employing another k-fold CV on the training 
set and the one generating the best results on the internal validation set was chosen. A summary of Raman image 
data analysis can be seen in Supplementary Figure S5.
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